Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 113

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 113
---
3.0 million and received $80 thousand in proceeds from disposition of marketable securities and purchased $19 thousand of equipment.

Cash Flows from Financing Activities

For the nine months ended September 30, 2024, we paid $0.8 million related to payments on a convertible note and $0.1 million for finance costs, and received $0.3 million of proceeds from a related party notes payable. For the nine months ended September 30, 2023, we received a net of $3.6 million from the sale and issuance of convertible notes payable and warrants and repaid $0.7 million in related party notes payable.

| 72 |

Results of Operations

Comparison of the year ended December 31, 2023 and 2022 (as restated)

The following table summarizes the results of our operations:

|                                                                               |     |  Years Ended |            |   |     |              |            |   |     |        |            |   |     |   |       |    |
|                                                                               |     | December 31, |            |   |     |              |            |   |     |        |            |   |     |   |       |    |
|                                                                               |     |         2023 |            |   |     |         2022 |            |   |     | Change |            |   |     | % |       |    |
|                                                                               |     |              |            |   |     | -as restated |            |   |     |        |            |   |     |   |       |    |
| Revenue                                                                       |     |            $ |          — |   |     |            $ |          — |   |     | $      |          — |   |     |   |     — |    |
| Operating expenses:                                                           |     |              |            |   |     |              |            |   |     |        |            |   |     |   |       |    |
| Research and development, net of contract expense reimbursements, as restated |     |              |  3,517,093 |   |     |              |  1,047,385 |   |     |        |  2,469,708 |   |     |   |   236 | %  |
| General and administrative, as restated                                       |     |              |  1,046,854 |   |     |              |    473,714 |   |